ArticleJournal of translational medicine2025
ZDHHC9 and spermine metabolism: a palmitoylation-driven pathway to prostate carcinogenesis.
Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The emerging role of ZDHHC9 in cancer: from protein palmitoylation to tumor progression and immune regulation.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSpermine is a natural metabolite that has been shown to hinder the progression of prostate cancer. Protein palmitoylation, a recently identified post-translational lipid modification, is catalyzed by a family of 23 enzymes known as zinc finger DHHC-type palmitoyltransferases (ZDHHCs). This study primarily investigates the role of ZDHHC9 in spermine metabolism and its potential association with prostate cancer.
methodsWe employed immunohistochemistry, Western blotting, and RT-qPCR techniques to assess ZDHHC9 expression in prostate cancer tissues and cell lines. The connection between ZDHHC9 and prostate cancer growth was analyzed using xenograft models, CCK-8 assays, and colony formation experiments. Additionally, we utilized mass spectrometry and RNA sequencing to elucidate how ZDHHC9 modulates spermine metabolism.
resultsZDHHC9 was found to be upregulated and appeared to function as an oncogene in prostate cancer. Both in vitro and in vivo functional experiments confirmed that ZDHHC9 facilitated prostate cancer proliferation and enhanced spermine catabolism in a palmitoylation-dependent manner. Mechanistically, ZDHHC9 interacted with hnRNPU and increased its protein stability through S-palmitoylation at the Cys497 and Cys607 residues. Moreover, the S-palmitoylation of hnRNPU mediated by ZDHHC9 could elevate the expression of SAT1, an enzyme responsible for spermine catabolism, by promoting its transcription.
conclusionsOur findings establish a new correlation between palmitoylation, spermine metabolism, and prostate carcinogenesis. Targeting the ZDHHC9-hnRNPU-SAT1 signaling axis might provide a novel therapeutic strategy for prostate cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.